The seminal discovery of enhanced antitumor immunity by blockade of the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) by Allison and colleagues in 1996 [83] has led to the rapid development and uptake of immunotherapy as standard of care for many types of cancer [84,85]. This evidence concerns the gene CTLA4 and cancer.